Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nephraegis Therapeutics Inc.
Headquarters: Lake Forest, IL, United States of America
Website: https://www.nephraegis.com/
Year Founded: N/A
Status: Private
BioCentury | May 15, 2021
Deals
May 14 Quick Takes: With PNH approval, Apellis’ development partner due for payouts; plus Vera, Kinnate, Nephraegis, Shifa, Grove and more
Now that FDA has approved Empaveli pegcetacoplan from Apellis Pharmaceuticals Inc. (NASDAQ:APLS) to treat paroxysmal nocturnal hemoglobinuria, the risk-sharing entity that funded Empaveli’s
BioCentury | May 13, 2021
Finance
Latest Garabedian-led Perceptive Xontogeny fund to deploy $515M in search of ‘transformational’ assets
New fund 2x the size of debut venture vehicle
Items per page:
1 - 2 of 2